Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

homoharringtonine

(hoh-moh-HAYR-ing-tuh-neen)
A drug used to treat adults with certain types of chronic myelogenous leukemia that cannot be treated with tyrosine kinase inhibitors (a type of anticancer drug) or that have not gotten better after treatment with at least two tyrosine kinase inhibitors. It is also being studied in the treatment of other types of cancer. Homoharringtonine blocks certain proteins involved in cell growth and may kill cancer cells. It is a type of plant alkaloid and a type of protein synthesis inhibitor. Also called omacetaxine mepesuccinate and Synribo.
More Information
Search NCI's Dictionary of Cancer Terms